RADLY:OTC-Raia Drogasil SA ADR (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 4.65

Change

-0.29 (-5.87)%

Market Cap

USD 7.74B

Volume

0.09M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. It sells its products through stores, telesales, and call centers in the states of São Paulo, Tocantins, and Pernambuco. The company was founded in 1905 and is headquartered in São Paulo, Brazil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.16B
JDHIF JD Health International Inc

N/A

USD 9.97B
ALBHF Alibaba Health Information Tec..

N/A

USD 8.27B
CLCGY Clicks Group Ltd

+0.63 (+1.50%)

USD 5.11B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.23B
SAEYY Shop Apotheke Europe N.V

N/A

USD 3.16B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

-3.47 (-8.17%)

USD 0.54B
NVACF Nova Cannabis Inc

N/A

USD 0.08B
PNPL Pineapple Express

N/A

USD 0.01B

ETFs Containing RADLY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -87.58% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.58% 12% F 6% D-
Trailing 12 Months  
Capital Gain -82.82% 12% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.82% 12% F 7% C-
Trailing 5 Years  
Capital Gain -83.26% 43% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.26% 43% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 7.13% 44% F 49% F
Dividend Return 7.89% 44% F 47% F
Total Return 0.76% 50% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 44.13% 80% B- 56% F
Risk Adjusted Return 17.87% 68% D+ 52% F
Market Capitalization 7.74B 86% B+ 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.